| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2007, p. 421-425, Vol. 45, No. 2
0095-1137/07/$08.00+0 doi:10.1128/JCM.00894-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, University of Antwerp UIA, Antwerp, Belgium
Received 28 April 2006/ Returned for modification 22 June 2006/ Accepted 5 December 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
A high-quality nucleic acid extract is expected to be free of amplification inhibitors and other substances that might affect enzyme substrates, and the target should be optimally recovered.
The NucliSens easyMAG platform (bioMérieux, Boxtel, The Netherlands) is a second-generation system for automated isolation of nucleic acids from clinical samples based upon silica extraction technology (3). It is a benchtop instrument with the same reagents as the manual version, i.e., NucliSens miniMAG platform (bioMérieux) (4, 14, 17, 19). Manual steps are limited to the loading of samples, reagents, and disposables. One to 24 samples can be analyzed in one run. The extraction method is universal and can be applied to a broad range of different specimens such as blood, sputum, serum, and throat swabs. The instrument can be used in combination with different amplification methods such as nucleic acid sequence-based amplification (NASBA) or PCR. Limited data are available on the NucliSens easyMAG extraction procedure (19).
The objectives of this study were to evaluate the performance and user convenience of the NucliSens easyMAG platform for the extraction of nucleic acid from different clinical specimens in comparison to those of QIAGEN extraction and NucliSens miniMAG extraction.
| MATERIALS AND METHODS |
|---|
|
|
|---|
From 24 cytomegalovirus (CMV) DNA-positive EDTA blood specimens from transplant patients, nucleic acids were isolated after storage for up to 3 months at 20°C without the addition of lysis buffer, except for 6 EDTA blood samples which were analyzed as fresh specimens.
Nucleic acid extraction. Mycoplasma pneumoniae and Chlamydia pneumoniae DNAs were extracted from 215 throat swabs with the QiaAmp blood mini kit (QIAGEN, Hilden, Germany) according to the instructions of the manufacturer. Elution was done in 100 µl of elution buffer. From a second aliquot of the 215 specimens, M. pneumoniae and C. pneumoniae RNAs were extracted by the NucliSens miniMAG platform with the NucliSens magnetic extraction reagents (bioMérieux, Boxtel, The Netherlands) according to the instructions of the manufacturer. Elution of these nucleic acid extracts was done in 20 µl. The third aliquot was subjected to the NucliSens easyMAG platform for total nucleic acid extraction (bioMérieux) by the off-board protocol according to the instructions of the manufacturer. Nucleic acids were eluted in 20 µl of elution buffer.
CMV DNA was extracted from 200 µl of EDTA blood with the QiaAmp blood mini kit (QIAGEN) according to the instructions of the manufacturer. Nucleic acids were eluted in 75 µl of elution buffer. A similar sample volume was retrospectively used for NucliSens easyMAG extraction by the off-board protocol. Nucleic acids from the EDTA blood were eluted in 60 µl. This volume was chosen since it was not possible to elute in 75 µl with the easyMAG.
In this study, the QIAGEN nucleic acid extraction system and the NucliSens miniMAG platform were used as reference methods for extraction of DNA and RNA, respectively.
Nucleic acid amplification assays. Nucleic acid extracts from the 215 throat swabs obtained with the NucliSens miniMAG and NucliSens easyMAG were investigated by real-time NASBA with the NucliSens EasyQ M. pneumoniae assay and the NucliSens EasyQ C. pneumoniae assay (bioMérieux) according to the instructions of the manufacturer. Both assays contain internal control RNA.
The amplification process was run in a fluorescence reader, the NucliSens EasyQ Analyzer (bioMérieux). The results obtained with the NucliSens Easy Q assay were calculated with the NucliSens EasyQ software and were classified as positive, negative, or invalid if the internal control was not detected or the signal was too weak. In negative control reaction mixtures, the target nucleic acid was replaced with RNase- and DNase-free water.
M. pneumoniae (22) and C. pneumoniae real-time PCRs (6) were done as described previously. For the detection of CMV, real-time PCR with the LightCycler was performed according to Stöcher (18).
Reproducibility of QIAGEN and NucliSens easyMAG extraction. The intrarun variations in extraction by both QIAGEN and NucliSens easyMAG were estimated by extracting five aliquots of the same CMV-positive EDTA blood sample within the same run by each method.
| RESULTS |
|---|
|
|
|---|
|
Statistical analysis. For the throat swabs (raw data, being either positive or negative), there was one specimen which was found positive only after QIAGEN extraction and real-time PCR amplification and detection. This is not statistically significant. In addition, looking in more detail at the data (Ct values) showed improvements in Ct values after NucliSens easyMAG extraction.
EDTA blood. Real-time PCR detected CMV DNA in nucleic acids extracts from EDTA blood from 24 patients. All six fresh blood sample extracts were found to be positive after both QIAGEN and NucliSens easyMAG nucleic acid extraction. The differences between the mean LightCycler Ct values obtained after NucliSens easyMAG extraction and QIAGEN extraction were 5.5, 1.82, 1.17, 0.67, 0.39, and +1.3. For the other 18 samples stored for up to 3 months at 20°C before extraction by the NucliSens easyMAG, 15 nucleic acid extracts were found to be positive after easyMAG extraction. Two out of these three patients scored negative in combination with NucliSens easyMAG extraction were known CMV-positive transplant patients, and re-extraction with QIAGEN and reamplification confirmed the results. In contrast, the third patient (Table 2, patient 2) had never been found to be CMV positive before and re-extraction with QIAGEN and reamplification did not confirm the positive result. An overview of these results is presented in Table 2.
|
Reproducibility of QIAGEN and NucliSens easyMAG extraction. The QIAGEN intrarun coefficient of variation and standard deviation are 3.540 and 1.212, respectively. For the NucliSens easyMAG extraction, an intrarun coefficient of variation and standard deviation of 1.239 and 0.440, respectively, were obtained.
User convenience of the NucliSens easyMAG. The NucliSens easyMAG represents a universal highly flexible extraction instrument with which (i) different sample input and elution volumes within the same run are possible, (ii) 1 to 24 samples can be treated in one run, and (iii) DNA and RNA extraction can be performed within the same run. Furthermore, the same NucliSens easyMAG nucleic acid extract can be used for both RNA and DNA amplification. The turnaround time for DNA or RNA extraction with the NucliSens easyMAG was reduced to 40 min for 24 samples by the off-board protocol, including about 10 min of hands-on time, whereas nucleic acid extraction of 12 samples by QIAGEN takes 50 min starting from the addition of the lysis buffer. The consumable and disposable costs for QIAGEN DNA extraction, QIAGEN RNA extraction, and NucliSens easyMAG DNA or RNA extraction were $4.10, $5.00, and $7.90, respectively.
| DISCUSSION |
|---|
|
|
|---|
The purpose of this study was to evaluate the performance and user convenience of the NucliSens easyMAG platform for the isolation of RNA and/or DNA from throat swabs and EDTA blood and from various organisms. In this study, the QIAGEN nucleic acid extraction system and the NucliSens miniMAG platform were used as reference methods for DNA and RNA extraction, respectively.
Real-time PCR detected M. pneumoniae and C. pneumoniae in 10 and 5 throat swabs after QIAGEN extraction and in 9 and 5 swabs after NucliSens easyMAG extraction. For the detection of the positive specimens, the difference between the LightCycler Ct values obtained after NucliSens easyMAG extraction and QIAGEN extraction varied between 6.62 and 0.6, resulting from a higher DNA yield or from fewer inhibitors being present in the nucleic acid extract. In most cases, better results were obtained after easyMAG extraction, even when the specimen was stored for more than 1 year at 70°C in the absence of a stabilizing lysis buffer, meaning that DNA degradation did not occur frequently. It could also not be related to inter- or intrarun variations since, e.g., the mean crossing point for M. pneumoniae real-time PCRs for amplification of the lowest dilution was 26.64 with a standard deviation of 0.056 while the mean crossing point for amplification of the highest dilution was 33.48 with a standard deviation of 0.315. For calculation of interassay variation, the mean crossing point was 33.81 with a standard deviation of 0.457. Similar inter- and intrarun variations were obtained for C. pneumoniae real-time PCR. One specimen was repeatedly M. pneumoniae positive after QIAGEN extraction but negative after NucliSens easyMAG extraction. The LightCycler Ct value suggests that the sample contained very small amounts of DNA, which could have been degraded after 1 year of storage at 70°C in the absence of a nucleic acid stabilizing buffer.
Lower LightCycler Ct values were obtained in 14/21 (66%) of the NucliSens easyMAG nucleic acid extracts from the EDTA CMV-positive blood samples, again suggesting that a higher DNA yield or a cleaner nucleic acid extract could be obtained after NucliSens easyMAG extraction. Three discordant results were obtained (patients 2, 9, and 12), all in cases where the LightCycler Ct values indicated that small amounts of CMV DNA were present in the sample. Two of these transplant patients were known to be CMV positive; one patient had never been found to be CMV positive before. After re-extraction in duplicate with QIAGEN and reamplification, negative results were obtained for the latter. The positive result was probably due to carryover contamination. The EDTA specimens from the other two patients were selected on the basis of PCR positivity for CMV and retrospectively analyzed by the NucliSens easyMAG. The negative results might be due to DNA degradation.
Other data from the literature indicate also that the sensitivity of a nucleic acid amplification assay after nucleic acid extraction with an automated system is similar to or better than the sensitivity obtained after manual nucleic acid extraction. When Wilson et al. (24) compared five commercially available methods for extraction of Legionella pneumophila from respiratory specimens, higher concentrations of L. pneumophila DNA were recovered from sputum with the MagNa Pure LC (Roche Diagnostics) and the NucliSens extractor (bioMérieux) than by the manual methods, i.e., the High Pure PCR Template Preparation kit (Roche Diagnostics), the QiaAmp DNA Mini kit (QIAGEN), and the ViralXpress kit (Chemicon). Exner and Lewinski compared the MagNa Pure system with the QiaAmp DNA blood mini kit and with phenol-chloroform extraction for the detection of Borrelia burgdorferi DNA from various types of specimens (5). Comparable sensitivities for all of the methodologies were obtained with all specimen types except urine, in which case QiaAmp extraction was two times less sensitive. On the other hand, Schuurman et al. (15) mentioned that MagNa Pure extraction of spiked CMV in whole blood showed a 5- to 10-fold reduction in PCR sensitivity compared to the manual nucleic acid extraction according to Boom et al. (3). On the basis of our present knowledge, it would be of interest to compare the NucliSens easyMAG platform with other automated nucleic acid extractors.
NucliSens easyMAG extraction is an improvement over NucliSens miniMAG extraction in terms of user friendliness, whereas both methods are comparable in extraction efficiency in terms of RNA recovery.
Similar findings were reported by Tang et al. (19), who validated the NucliSens easyMAG by using 75 urine specimens for detection of the polyomavirus BK virus. Its sensitivity for detection of the BK virus was identical to that of the miniMAG, the MagNa Pure compact system, and the BioRobot EZ1. Its reproducibility was similar to that of the NucliSens miniMAG, and the human ß-actin gene was detected in 71 (94.7%) of the urine specimens.
The type of nucleic acid amplification test inhibitors present and the composition of the clinical specimen vary depending on the type of infecting organism and the site from which the clinical specimen was obtained. Since throat swabs represent the majority of respiratory specimens for detection of M. pneumoniae and C. pneumoniae in our laboratory and whole blood is used for CMV detection by nucleic acid amplification tests, the efficiency of nucleic acid extraction for M. pneumoniae, C. pneumoniae, and CMV in throat swabs and whole blood, respectively, was studied.
In the literature, inhibition of amplification in respiratory specimens varies between 0 and 25%, depending on the type of specimens used (2, 7, 20, 21, 23). The use of a sample integrity control such as U1A (12) or an internal control added to each sample could exclude false-negative results due to inhibitors present in respiratory specimens. The internal control included in the NucliSens EasyQ M. pneumoniae assay and the NucliSens EasyQ C. pneumoniae assay provides information about the performance of the extraction, amplification, and detection procedures and the quality of the reagents in each particular run. Without the internal control, 3.2 and 0.7% would have been reported negative by the NucliSens miniMAG and easyMAG, respectively. No invalid results were obtained after real-time PCR applied on the NucliSens easyMAG nucleic acid extract.
A major concern in the use of automated nucleic acid extraction is the risk of cross contamination of negative specimens by strongly positive specimens as a consequence of aerosols, leaking pipettes, or faulty robotics. No false-positive results were obtained after NucliSens easyMAG extraction, whereas one false-positive CMV result was suspected after QIAGEN extraction. These samples are a known risk in our laboratory for cross contamination during the numerous pipetting and centrifugation steps inherent in the manual extraction procedure. Manual extraction therefore requires more rigorous handling and expertise from the analyst. However, no carryover study was performed.
In this study, the NucliSens easyMAG extracted DNA and RNA more efficiently from clinical samples (higher recovery and/or fewer inhibitors) than did QIAGEN extraction by showing, on average, lower Ct values in the LightCycler real-time PCR assay. The instrument features user-friendly intuitive software; allows nucleic acid extraction from different types of specimens with different input and elution volumes, as well as DNA and RNA targets, in a single extraction run; and delivers high throughput capabilities with a 40-min turnaround time. The ability to extract the majority of samples automatically with such a generic extraction protocol can lead to a large reduction in the total turnaround time, especially since laboratories often use different manual sample preparation protocols and kits for DNA and RNA targets.
| FOOTNOTES |
|---|
Published ahead of print on 13 December 2006. ![]()
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|